Tarsus Pharmaceuticals Highlights Strong XDEMVY Sales Growth and Pipeline Progress in Corporate Presentation

summarizeSummary

Tarsus Pharmaceuticals filed an 8-K with a corporate presentation detailing strong XDEMVY sales, including Q3 2025 net sales of $118.7 million and FY 2025 guidance of $440-$445 million, alongside significant pipeline advancements for ocular rosacea and Lyme disease prevention.

check_boxKey Events

• Strong XDEMVY Sales Performance

  The company reported record Q3 2025 net sales of $118.7 million for XDEMVY, representing 147% year-over-year growth. It also provided Q4 2025 net sales guidance of $140-$145 million, leading to a full-year 2025 guidance of $440-$445 million.

• Pipeline Advancement in Ocular Rosacea

  Tarsus initiated a Phase 2 study for TP-04 (lotilaner ophthalmic gel) for the treatment of ocular rosacea in December 2025, with data expected in 1H 2027. This represents a potential first-in-class therapeutic for a pervasive condition.

• Lyme Disease Prevention Program Progress

  The company plans to initiate a Phase 2 study for TP-05 (oral lotilaner) for Lyme disease prevention in 2026, aiming to be the first and only on-demand oral prophylaxis for the growing public health crisis.

• Global Expansion Efforts

  Tarsus is on track for potential regulatory approval of XDEMVY in Europe by 2027 and has seen its New Drug Application for TP-03 (for Demodex blepharitis) accepted in China, with ongoing discussions in Japan for 2026.

auto_awesomeAnalysis

This 8-K filing, attaching a corporate presentation, provides a comprehensive and positive update on Tarsus Pharmaceuticals' commercial performance and pipeline development. The strong sales figures for XDEMVY, including record Q3 2025 net sales and robust Q4/FY 2025 guidance, reinforce the product's market penetration and the company's financial trajectory. Additionally, the initiation of a Phase 2 study for ocular rosacea (TP-04) and plans for a Phase 2 study in Lyme disease prevention (TP-05) demonstrate significant progress in expanding the company's therapeutic portfolio. These updates collectively strengthen the investment thesis by showcasing both current commercial success and future growth potential.